Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Bullboard Posts
Comment by valueplaysonlyon Mar 22, 2014 9:13am
324 Views
Post# 22355330

RE:RE:Yes, "by way of tweet"

RE:RE:Yes, "by way of tweet"
Ignore the paid basher. Their job was to drive it down from 75 cents to 25 cents. They succeeded. Now they want to slow the ascent back to 5 dollars so they can liquidate other positions and add. The simple fact is that their diagnostics coupled with Toraymyxin delivers the best results if sepsis is detected early ( with their device) and if Toraymyxin is administered fast. It has greater success in cases where the sepsis starts in the abdominal area. However given the high mortality rates of sepsis, the one-two punch of diagnostics plus toraymyxin does deliver a great result. Yes it is true that results fall off if the sepsis is discovered only a few days late. But given the high mortality rates of sepsis and how it shuts off organs quickly one cannot fault SDI if the medical hospitals are slow to detect it. The diagnostic gives results in 30 minutes after all. There is a bias in some medical literature that laments toraymyxin as not effective in late stage diagnostic and treatment and that is true, but early detection is the key in almost all diseases, so that's a mute point, or an idiot basher grasping for straws. The important point is that SDI has the diagnostic and the treatment and if both become standard operating procedure and are well inventoried in medical establishments this will be a huge winner. Again, there are no alternatives out there better now. Tell the FDA to tell the parent of a dead child you took away hope rather than take a chance. I think NOT. Winner winner or I'm a sinner.
Bullboard Posts